TITLE

Understanding clopidogrel efficacy in the presence of cytochrome P450 polymorphism

AUTHOR(S)
Turgeon, Jacques; Pharand, Chantal; Michaud, Véronique
PUB. DATE
June 2006
SOURCE
CMAJ: Canadian Medical Association Journal;6/6/2006, Vol. 174 Issue 12, p1729
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Comments on a study on the efficacy of the drug clopidogrel in the presence of cytochrome p450 polymorphism. Risk of atherothrombotic events in people taking clopidogrel; Frequency of atherothrombotic events in a follow-up period among patients who underwent coronary angioplasty with bare-metal stent implantation and antiplatelet therapy with clopidogrel; Role of platelets in the pathogenesis of atherothrombotic events.
ACCESSION #
21062831

 

Related Articles

  • Clopidogrel Bisulfate: A Review of its Use in the Management of Acute Coronary Syndrome. Rossini, Roberta; Musumeci, Giuseppe; Nijaradze, Tamar; Gavazzi, Antonello // Clinical Medicine: Therapeutics;2009, Issue 1, p899 

    Antiplatelet therapy is the cornerstone in the modern therapy of patients with acute coronary syndromes (ACS), because of the unique role of platelets in coronary thrombosis. Clopidogrel in combination with aspirin is the current "gold standard" for reducing cardiovascular events in such...

  • tirofiban.  // Davis's Drug Guide for Nurses, 10th edition;2007, p1153 

    This article presents a nurse's guide to the antiplatelet agent tirofiban. Tirofiban is indicated for the treatment of acute coronary syndrome, including patients who will be managed medically and those who will undergo percutaneous transluminal angioplasty or atherectomy. It acts by decreasing...

  • Percutaneous Coronary Intervention.  // Current Medical Literature: Interventional Cardiology Monitor;2006, Vol. 13 Issue 3, p78 

    The article assesses several studies regarding percutaneous coronary intervention. A study focused on the clinical challenges in major non-cardiac surgery. Another study concluded that abciximab lessen the complications of acute coronary syndromes in patients. One study dealt with dual...

  • Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. A. Palumbo; F. Gay; S. Bringhen; A. Falcone; N. Pescosta; V. Callea; T. Caravita; F. Morabito; V. Magarotto; M. Ruggeri; I. Avonto; P. Musto; N. Cascavilla; B. Bruno; M. Boccadoro // Annals of Oncology;Jun2008, Vol. 19 Issue 6, p1160 

    Background: Bortezomib has shown significant activity in myeloma. In this multicenter trial, we assessed for the first time the combination of bortezomib, doxorubicin and low-dose dexamethasone (PAd) in the treatment of relapsed/refractory myeloma. Patients and methods: Sixty-four patients were...

  • Spotlight on Eptifibatide in Patients with Acute Coronary Syndromes and/or Undergoing Percutaneous Coronary Intervention1. Curran, Monique P.; Keating, Gillian M. // BioDrugs;2006, Vol. 20 Issue 1, p63 

    Eptifibatide (Integrilin) is a highly specific, reversible, intravenously administered glycoprotein IIb/IIIa receptor antagonist that acts at the final common step of the platelet aggregation pathway.Data from large clinical trials indicate that intravenous eptifibatide as adjunctive therapy to...

  • Drug-Eluting Stent Thrombosis 1,659 Days after Stent Deployment. Al-Dehneh, Anthony; Virk, Hartaj; Alkhouri, Yazan; Hamdan, Aiman; Bikkina, Mahesh // Texas Heart Institute Journal;2010, Vol. 37 Issue 3, p343 

    Drug-eluting stents are considered to be superior to bare-metal stents in reducing restenosis rates at 6 months. However, drug-eluting stents appear to be subject to stent thrombosis, a concern that has been reported more frequently in recent times. In November 2003, a 64-year-old man with a...

  • Platelet inhibitors: Old and new uses. Glaser, Vicki // Patient Care;10/30/1999, Vol. 33 Issue 17, p111 

    Focuses on options for acute and long-term antiplatelet therapy. Challengers to aspirin's dominance in the antiplatelet field; Value of established drugs; Trends in the field of antiplatelet therapy; Utilization of abciximab in high-risk coronary balloon angioplasty. INSET: Newer medications..

  • PLATELETS MORPHOLOGICAL CHANGES IN ACUTE MYOCARDIAL INFARCTION AND ITS RELATIONSHIP TO ST SEGMENT CHANGES DURING THROMBOLYSIS. Soo, L.; Siotia, A.; Brummitt, D.; Barker, H. // Heart;May2004 Supplement 2, Vol. 90, pA31 

    This article focuses on a study that shows platelets morphological changes in acute myocardial infarction and its relationship to ST segment changes during thrombolysis. ADIVA 120 full blood count analyzer can provide rapid detail about platelet morphological changes using flow cytometry....

  • Relationship found between CYP2C19 and increased platelet reactivity in patients receiving clopidogrel.  // Cardiology Today;Sep2010, Vol. 13 Issue 9, p40 

    The article reports on the results of a Korean study on the relationship between cytochrome 2C19 variant and increased platelet reactivity in patients receiving high maintenance-dose clopidogrel.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics